Expression Analysis® Expands Sequencing Services

Single-Lane Sequencing with Guaranteed Turn Times and Firm-Fixed Pricing

DURHAM, N.C.--(BUSINESS WIRE)-- Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today that it has expanded its sequencing services to include single-lane sequencing with guaranteed turn-around-times and, firm fixed pricing. The new service will be offered on the Illumina GA II and will include the following applications: Shotgun Sequencing, ChIP Seq, mRNA Seq and small RNA Seq.

"We have seen significant demand for a program like this, mainly from individual researcher, only needing to sequence one or two specimens. We are filling a need but, most importantly, every project has access to our in-depth expertise in sequencing and bioinformatics,” stated Steve McPhail CEO and President of Expression Analysis. “Another very unique aspect of our single-Lane Sequencing Program (http://singlelane.expressionanalysis.com) is the Flow Cell Tracker. Clients will be able to login and track their specimen(s) throughout the sequencing process.”

The benefits of the program extend further than guaranteed turn-around and firm-fixed-pricing; clients will have the assurance their studies will be handled by a proven industry leader with an unmatched depth and breadth of genomic expertise.

About Expression Analysis, Inc.

Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichment technologies and bioinformatics support. Platforms utilized include Affymetrix GeneChip® and GeneTitan®, Applied Biosystems’ Taqman, Fluidigm’s Biomark and Access Array Systems, Illumina BeadChip® and Genome Analyzer, NanoString Technologies nCounter® Analysis System, RainDance Technologies RDT 1000 and, in the near future, the Pacific Biosciences™ PacBio RS. Expression Analysis offers solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. Our quality system follows CLSI guidelines and our CLIA-registered laboratory supports GLP compliance.



CONTACT:

Expression Analysis, Inc.
Karen Michailo, Senior Director of Marketing
919-287-4277 (office)
919-349-3687 (mobile)

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics

MEDIA:

Logo
 Logo

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.